This blog is written by Sally Church, Ph.D.
I am an English scientist (a biochemist), interested in the biology of cancer and write this blog in my spare time when not playing fantasy football.
My particular interests include oncology, hematology, respiratory and immunology.
Please understand that I’m not medically qualified and unable to advise any patients or caregivers what they should do with regards to medical treatment.
My academic qualifications include a Masters degree in Human and Applied Physiology and a Doctorate focusing on respiratory medicine, asthma and COPD, both from King’s College London (University of London).
In the US, I obtained an MBA from Rutgers, the State University of New Jersey, which had a focus on finance and economics. Originally, I spent 3 years studying Sport Science, majoring in biochemistry and physiology, gaining a Bachelor in Science degree (B.Sc. Hons) from John Moore’s University in Liverpool. This diversity of education in science and business has occasionally provided me with a well rounded approach to problem solving 🙂
Business-wise, I spent over 13 years working for Sandoz Pharmaceuticals in the UK and Novartis Pharmaceuticals in the US in a variety of different roles from strategic planning to sales, marketing, mature products (generics) and new product development. While in the US, I was lucky enough to work on Gleevec (imatinib) from phase I to phase IV, including several market launches in oncology such as CML and GIST. Sometimes, you look back and realise what an incredible experience it is to be part of a great team, both inside and outside the company. We were also fortunate to work with some wonderful doctors, nurses and patients who truly made a difference to people’s lives.
Of course, it goes without saying that the thoughts and opinions expressed are mine entirely, and not those of my employer or clients. Neither are any of these posts sponsored. I do hope you enjoy this blog as much as I enjoy researching the posts and topics discussed.
Update: I’ve not been updating the blog since 2014, so a lot of content is most likely out of date. Please don’t rely on it for accuracy. If you want to read my current posts, they are now on a subscription funded site, Biotech Strategy Blog. There are also excerpts from recent thought leader interviews on the Novel Targets Podcast, which is well worth a listen.